At the IGTP TODAY
The collaborative project InMaM, part of the Complementary Plan for Biotechnology Applied to Health, involving both Catalonia and the Basque Country, aims to discover new immunotherapy-based treatments for metastatic breast cancer.
A study co-led by researchers from IGTP, IIB Sant Pau and IDIBGI concludes that direct transport to a referral centre for endovascular treatment may not be the best option for patients with a final diagnosis of intracerebral haemorrhage or haemorrhagic stroke.
The Ibero-American network RIGHT PLUS, of which the CEEISCAT is a founding member and, together with Coalition Plus, co-coordinator, has presented its launch at a meeting in Buenos Aires (Argentina) on 28-29 August.
The research groups in Nursing Care (NURECARE) and Innovation, Health Economics and Digital Transformation (INEDIT) from the IGTP are leading the publication of the first report on the key factors for introducing digital technologies in professional nursing practice environments. Through this effort, professionals from the Germans Trias Hospital are participating for the first time in the design of a comprehensive analysis of the required changes, while also offering recommendations to ensure the success of any initiative aimed at incorporating these technologies into hospitals.
The Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) has published the final resolution of the call for grants to support the activities of research groups in universities, centres and foundations. In this year's call, 21 IGTP groups have been recognised as Consolidated or Emerging Research Groups, 7 of which will receive funding totalling €340,000.
_1681823569.jpg)
Encouraging news in the framework of the International Day Against Childhood Cancer. The Spanish Association Against Cancer, through its Aid Programmes, has granted 1.2 million euros to the coordinated project "Personalised Medicine for Childhood Liver Cancer". The five-year project will be coordinated by the Germans Trias i Pujol Research Institute (IGTP), under the leadership of Dr Carolina Armengol, with the participation of another four Spanish research groups. All participating groups are members of the CIBER of Hepatic and Digestive Diseases (CIBEREHD).
The Centre for the Development of Industrial Technology (CDTI) and the Carlos III Health Institute (ISCII) will fund the project with 1.8 million euros within the R&D&I call linked to Personalised Medicine and Advanced Therapies in the framework of the Strategic Project for the Recovery and Economic Transformation for Vanguard Health (PERTE for Vanguard Health) in gene therapy for Friedreich's ataxia.
The COVICAT-CONTENT 2023 study begins today, with the aim of monitoring COVID-19 in different cohorts in Catalonia and the rest of Spain. Researchers from the Barcelona Institute for Global Health (ISGlobal) and the GCAT'Genomes for Life project of the Germans Trias i Pujol Research Institute (IGTP) evaluate the genetic and epidemiological determinants associated with the disease, as well as the long-term effects of the pandemic on people's physical and mental health and the evolution of the immune response. In this way, the objective is to help define predictive models and control policies for similar situations in the future.
Researchers from the Clinical Genomics Group at Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service at Germans Trias i Pujol Hospital (HUGTiP) will coordinate the project EURONET-NF, which aims to improve genetic diagnosis for patients with neurofibromatoses and schwannomatosis (NF-SWN). The project, which involves 6 countries, has been awarded around €1.6 million in funding by the European Union for the next 3 years.Researchers from the Clinical Genomics Group at Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service at Germans Trias i Pujol Hospital (HUGTiP) will coordinate the project EURONET-NF, which aims to improve genetic diagnosis for patients with neurofibromatoses and schwannomatosis (NF-SWN). The project, which involves 6 countries, has been awarded around €1.6 million in funding by the European Union for the next 3 years.
The European Commission has granted two projects to the IGTP within the HORIZON programme, which add up to a total of 1,670,346 euros in funding and deal with the preclinical development of immunotherapies.
